CS MEDICA announces voluntarily extension of lock-up agreement for CEO and CFO


CS MEDICA A/S reported today that CEO Lone Henriksen as well as CFO Gitte Lund Henriksen have extended their lock-up agreements for their shares in the Company until August 2023. In total, the lock-up agreements correspond to approximately 74 percent of the votes and capital in CS MEDICA.

CEO Lone Henriksen and CFO Gitte Lund Henriksen at CS MEDICA have extended their existing lock-ups for 12 months until end of August 2023. The original lock-up agreement was entered in connection with the listing on Spotlight Stock Market in August 2021. The lock-up prevents the selling of shares.

“We strongly believe in CS MEDICA’s bright future and by extending our lock-up agreement it reconfirms our commitments to the future development of the Company and we have no intention of selling our shares now,” says CEO Lone Henriksen.

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

Leave a Reply

Your email address will not be published. Required fields are marked *